### Common Drug Review *

#### Submission Status

**Product:** Lyrica  
**Generic Name:** pregabalin  
**Manufacturer:** Pfizer Canada Inc.  

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Submission Received:</td>
<td>2005-Nov-16</td>
<td>Targeted CEDAC Meeting:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Target Date Time (Business Days) | Target Date** | Actual CDR Date | Comments |
--- | --- | --- | --- |
1 | Submission Deemed Complete | 5 | 2005-Jul-05 | 2005-Jul-05 |  |
2 | CDR Reviewers’ Reports Completed  
• Reviewers selected and contracted  
• Literature search and selection completed  
• Systematic review of clinical data completed  
• Critical appraisal of pharmacoeconomic (PE) data completed  
• Clinical and PE reports written  
• Reports edited and finalized  
• Reviewers’ reports sent to manufacturer | 45 | 2005-Sep-08 | 2005-Sep-08 | Additional information requested July 11, 2005.  
Additional information requested July 19, 2005.  
Additional information received July 21, 2005.  
Additional information received July 25, 2005.  
Additional information requested August 3, 2005.  
Additional information received August 5, 2005.  
Additional information requested August 17, 2005.  
Additional information received August 25, 2005. |
3 | Comments from Manufacturer on Reviewers’ Reports Received by CDR | 7 | 2005-Sep-19 | 2005-Sep-16 |  |
Additional information received September 26, 2005. |
5 | CEDAC Brief Completed and Sent to CEDAC Members | 5 | 2005-Nov-02 | 2005-Nov-02 |  |
6 | CEDAC Meeting | | 2005-Nov-16 | 2005-Nov-16 |  |
8 | Embargo Period***  
Managers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10 | 2005-Dec-07 | 2005-Dec-07 |  |
9a | Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(No Requests for Clarification are made) | 5 | 2005-Dec-07 | 2005-Dec-07 |  |
9b | Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(Clarification Requested, no Request for Reconsideration made) | 5 | 2005-Dec-07 | 2005-Dec-07 |  |
9c | Placed on CEDAC Agenda For Reconsideration  
(At Manufacturer’s request) | 25 | 2006-Jan-18 | 2006-Jan-18 |  |
10 | Final Recommendation sent to Drug Plans, ACP, and Manufacturer | 5 | 2006-Jan-25 | 2006-Jan-25 |  |

---

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.ccohta.ca.  
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.  

January 27, 2006